With increasing numbers of long-term gynaecological cancer survivors, the prevention and alleviation of late side effects after treatment have become a priority. A significant number of these survivors have been treated with pelvic radiation therapy. Radiation therapy may induce pathophysiological changes in all normal tissue or organs within the irradiated volume, which in some cases will lead to symptoms negatively affecting daily activities and quality of life. Although some late effects from normal tissues have been extensively explored ([@bib16]; [@bib19]; [@bib11]; [@bib28]), others have been less characterised ([@bib7]).

The mechanism leading to radiotherapy-induced late side effects is multifactorial. Irradiation may induce direct cell killing through DNA double-strand breaks. However, the interaction of ionising radiation with normal tissue also induces activation of cytokines and growth factors leading to a risk of fibrosis with decreased elasticity and compliance and increased risk of strictures. In addition, impaired function in blood- and lymph vessels along with neural damage may enhance the effect ([@bib12]; [@bib6]; [@bib20]). Severe acute side effects have also been associated with consequential late effects in normal tissue ([@bib14]). Together with patient characteristics, such as smoking, co-morbidities and genetic factors, these radiation-induced effects may lead to changes affecting specific physiological functions ([@bib2]; [@bib7]).

Radiation oncologists have a long tradition of recording late toxicity after cancer treatment. Several instruments exist, for example, the Franco-Italian glossary ([@bib33]), the RTOG/EORTC late radiation morbidity scoring schema ([@bib32]), the SOMA-LENT system ([@bib27]) and CTCAE ([@bib38]), but many of these combine multiple signs and symptoms into a single grade leading to loss of specificity. Only rarely have the toxicity scales been developed with guidance from the survivors. In addition, the great variety of study designs and measures of quality of life used in studies of gynaecological cancer survivors may make comparisons difficult. Although many of the questionnaires commonly used in clinical trials have been validated, for example, the FACT ([@bib10]) and EORTC QLQ ([@bib35]) questionnaires, these do not explore the impact of each specific symptom on daily activities ([@bib36]).

Personal identity numbers and official population-based registers in Sweden covering all Swedish citizens offer exceptionally good conditions for studying cancer survivors without selection-induced problems. We performed a population-based cohort study on gynaecological cancer survivors concerning late symptoms after pelvic radiation therapy. We used a validated study-specific questionnaire in order to cover specific physical symptoms, sexuality, psychological dimensions and their impact on social functioning since no standardised existing instruments measure all these aspects. Here, we present self-reported symptoms from irradiated normal tissues, that is, the anal sphincter, the bowel, the urinary tract, the pelvic bones, the lower abdomen, legs and symptoms related to sexuality among gynaecological cancer survivors and compare their occurrence with that of population-based control women. In addition, we present a detailed description of the demographic and clinical characteristics and how therapy was delivered in order to provide a background for coming publications.

Materials and methods
=====================

Study population
----------------

A cohort of 1800 women treated with external pelvic radiation therapy alone or as part of combination therapy for a gynaecological malignancy was identified. The women were consecutively treated between February 1991 and December 2003 at Radiumhemmet, Karolinska University Hospital in Stockholm or at Jubileumskliniken, Sahlgrenska University Hospital in Gothenburg ([Figure 1](#fig1){ref-type="fig"}). At follow-up in January 2006, 789 survivors (Stockholm *n*=595 and Gothenburg *n*=194) met the eligibility criteria, that is, born 1927 or later, being able to read and understand Swedish, and having no recurrent disease. Eligible survivors received an introductory letter. Medical records were reviewed to confirm the cancer diagnosis, stage of disease and treatment techniques regarding surgery, radiation therapy and chemotherapy.

As controls, we recruited 478 women from the Swedish Population Register, matched for age and residency and who had not had pelvic radiation therapy ([Figure 1](#fig1){ref-type="fig"}). An error in the matching procedure led to a younger control population (median age 57.5) compared with the cancer survivors (median age 66.0), which was adjusted for in the statistical analyses. The Regional Ethics Committee at the Karolinska Institute approved the study.

Questionnaire
-------------

Our methods for studies of cancer survivorship and development of study-specific questionnaires have been documented in \>80 scientific papers ([@bib8]; [@bib37]). A description of the development and validation of the present questionnaire has previously been reported ([@bib15]). In summary, the questionnaire was developed during an 18 months long qualitative phase including semi-structured interviews with 26 gynaecological cancer survivors previously treated with pelvic radiation therapy. A study-specific questionnaire was constructed consisting of 351 questions covering symptoms from the gastrointestinal tract, urinary bladder, genitals, pelvic bones, abdomen and legs. Questions concerning demographics, sexual function, intercurrent diseases, psychological and quality-of-life issues were included. In each part of the questionnaire, we asked about the incidence, prevalence, intensity and duration of the symptoms and their impact on different aspects of social functioning.

Face-to-face validation of the final version was made to ensure that it was conceivable and had satisfactory internal consistency. Participation rate and rate of missing values were tested in a pilot study. The main study, the quantitative phase, was carried out during January--October 2006. Eligible women who gave informed consent received a postal questionnaire. Confidentiality was maintained by numbering the questionnaires.

Radiation therapy
-----------------

Treatment was administered according to local treatment programmes and applied study protocols that were ongoing at the time of treatment. External beam radiation therapy (EBRT) was based on computed tomography (CT) scans performed before radiation therapy. Computed tomography scans were made in treatment position on a flat table top, using laser markers and conversion factors to electron density. Computed tomography slices ranged from 5 to 20 mm. The EBRT dose was prescribed either at isocenter or as mean dose to the target covering at least 95% of the planning target volume ([@bib21]). Patients were treated in supine position, using linear accelerators or a racetrack accelerator with two opposing fields or a four-field box technique. Daily dose per fraction varied between 1.6 and 2.0 Gy. External beam radiation therapy was verified by portal image films and with check-and-confirm systems. Brachytherapy (BT) was applied using standardised techniques and applicator templates. The BT dose was prescribed according to local practice. Pre-treatment orthogonal X-ray images verified the position of the BT applicator.

A detailed description of treatment techniques in relation to cancer diagnosis is provided in the [Supplementary Appendix Table A1](#sup1){ref-type="supplementary-material"}. For radiograph figures of typical treatment; see the [Supplementary Appendix Figures A1--A4](#sup1){ref-type="supplementary-material"}.

Statistical analyses
--------------------

The results from the questionnaire and the data from the medical records were coded and transferred to the freeware data-entry program Epi-Data (<http://www.epidata.dk>). We used Fisher\'s exact test (Monte Carlo approximation, 10^7^ samples) to test for differences in survivors and control characteristics ([Table 1](#tbl1){ref-type="table"}). The test was two-sided and at the 5% significance level.

Different cut-off levels were used to describe the frequency of symptom occurrence. For initial analyses, a symptom was dichotomised into having the symptom occasionally or more often and into not having the symptom at all the past 6 months. In the final analyses, the cut-off level was changed into at least once a week in symptoms that had a high prevalence, that is, exceeding 45% in controls. We calculated the proportions having each outcome (symptom) among cancer survivors and control women, and used relative risk (RR) defined as the ratio between these proportions as outcome measure. Age-adjusted RRs with 95% confidence intervals (CIs) were calculated according to the log-binomial model ([@bib26]) including age as a categorical covariate with the categorisation used in [Table 1](#tbl1){ref-type="table"}. Individuals with missing data were excluded from the calculations of each respective outcome. All calculations were performed using the SAS statistical software package (version 9.2, SAS Institute Inc., Cary, NC, USA).

Results
=======

In all, 616 of 789 (78%) cancer survivors and 344 of 478 (72%) control women returned a completed questionnaire and participated in the study ([Figure 1](#fig1){ref-type="fig"}). Median follow-up time was 74 months with a range of 26--179 months.

The median age for cancer survivors was 66.0 years and for control women 57.5 years ([Table 1](#tbl1){ref-type="table"}). Cancer survivors were more often single, had a lower level of education, lower degree of physical activity and were more often on disability pension compared with control women.

Nulliparity was twice as common among the survivors. Operational procedures at delivery and vaginal or perineal injury were less common among cancer survivors. The most common co-morbidity among cancer survivors was hypertension occurring in 38%, compared with 27% in control women. Diabetes mellitus and heart failure were also more prevalent among cancer survivors. Endometrial cancer and cervical cancer were the most common diagnoses. In all, 84% of the cancer survivors were treated for stage I--II disease.

Overall 90% of the gynaecological cancer survivors were treated with surgery and EBRT with or without BT and chemotherapy. The remaining 10% consisted of a subset of cervical and vaginal cancer patients treated with radiation therapy alone ([Figure 2](#fig2){ref-type="fig"}). Additional information on demographic and clinical characteristics as well as a detailed description of treatment in relation to cancer diagnosis is provided in the [Supplementary Appendix Table A1](#sup1){ref-type="supplementary-material"} and [Supplementary Appendix Table A2](#sup1){ref-type="supplementary-material"}. Treatment schedules for ovarian and fallopian tube cancer were identical and the results are hence presented together.

Symptoms associated with cancer therapy
---------------------------------------

With a median follow-up time of 6.2 years, cancer survivors reported a higher occurrence of symptoms from the anal sphincter, the bowel, the urinary tract, symptoms related to sexuality, the pelvic bones and the lower abdomen and legs, compared with control women ([Table 2](#tbl2){ref-type="table"} and [Supplementary Appendix A3](#sup1){ref-type="supplementary-material"}).

The highest age-adjusted RR among anal-sphincter symptoms was for 'emptying of all stools into clothing without forewarning\', RR 12.7 (95% CI 4.0--40.3) with a prevalence of 12% among survivors and 0.9% among control women. This symptom was reported by one-third of the survivors with uterine sarcoma compared with 9% among survivors with endometrial and ovarian cancer. The prevalence of symptoms in relation to diagnosis is provided in the [Supplementary Appendix Table A4](#sup1){ref-type="supplementary-material"}. The occurrence of symptoms from the anal sphincter and bowel was in general higher among survivors with uterine sarcoma, cervical and vaginal cancer compared with endometrial and ovarian cancer survivors.

The highest age-adjusted RRs among urinary tract symptoms were observed for 'difficulty feeling the need to empty the bladder\' (RR 2.8; 95% CI 1.5--5.4) with a prevalence of 9% in survivors compared with 3% in control women. The corresponding figures for 'difficulty feeling a full bladder\' (RR 2.7; 95% CI 1.6--4.5), was 15% in cancer survivors compared with 5% in control women. These symptoms occurred more frequently among survivors treated with radiation therapy alone compared with those treated with surgery and radiation therapy.

For symptoms related to sexuality, 34% of the survivors reported 'absence of vaginal elasticity\' compared with 14% among control women (RR 1.8; 95% CI 1.3--2.4). This symptom occurred in 47% of survivors treated with radiation therapy alone. 'Deep dyspareunia when having intercourse\' occurred in 17% of cancer survivors irrespective of treatment modality, compared with 7% among control women (RR 3.7; 95% CI 2.4--5.7). About one-third of the survivors reported a 'decreased ability for intercourse leading to a lower intercourse frequency\'.

Pubic bone pain was at least three times as common among survivors compared with control women. The highest age-adjusted RR was for 'pubic pain when walking indoors\', RR 4.9 (95% CI 2.1--11.6). Among survivors treated with radiation therapy alone, this symptom was reported by 18% compared with 2% among control women (RR 10.3; 95% CI 4.0--26.7).

For the abdomen and legs the highest age-adjusted RR was for 'erysipelas on abdomen or legs\', RR 3.6 (95% CI 1.0--12.8) followed by 'lower abdominal heaviness\', RR 2.1 (95% CI 1.5--3.0) occurring in one-fifth of the survivors. The prevalence among survivors treated with radiation therapy alone was 30%, compared with 11% among control women.

Discussion
==========

Gynaecological cancer survivors treated with pelvic radiation therapy alone or as part of combined treatment reported higher occurrence of late specific symptoms from all normal tissues addressed in the study, that is, the anal sphincter, the bowel, the urinary tract, the pelvic bones, the lower abdomen and legs as well as symptoms related to sexuality compared with matched control women.

Although gastrointestinal side-effects following pelvic radiation therapy are well documented, the occurrence and specificity of anal sphincter and bowel symptoms in long-term survivors have been less well studied ([@bib3]; [@bib31]). We have in a previous publication reported on our findings of higher occurrence of gastrointestinal symptoms and a 12-fold higher occurrence of emptying of all stools into clothing without forewarning among long-term gynaecological cancer survivors compared with controls. This severe faecal incontinence symptom was more prevalent in survivors treated for cervical cancer and uterine sarcoma. These diagnoses had in general higher median EBRT doses. In a previous study from our group, 65 prostate cancer survivors were asked by means of a study-specific postal questionnaire about bowel and urinary symptoms and sexual function 2--4 years after curative EBRT to the prostate. A correlation was found between the dose to the anal sphincter and faecal leakage in the interval of 45--55 Gy and also a correlation between defaecation urgency and loose stools and the dose to the rectum in the interval of 25--42 Gy ([@bib1]). It is reasonable to also investigate the impact of dose to bowel and anal sphincter in relation to the occurrence of emptying of all stools without forewarning.

The urinary bladder has been regarded as less radiosensitive compared with the bowel ([@bib25]). Late urinary side-effects appear to be less common but there are few published reports on the prevalence of specific urinary symptoms among long-term gynaecological cancer survivors. With median follow-up of 60 and 68 months, the PORTEC-1 trial reported a prevalence of 8% of mild genitourinary complications (measured by French-Italian glossary), while the GOG99 trial reported a 25% genitourinary complication rate (assessed by the 1985 GOG Adverse Events Criteria scale) after postoperative EBRT in women with early stages of endometrial cancer ([@bib11]; [@bib23]). In the PORTEC-1 trial, the complications consisted of urinary urgency, recurrent urinary infections and minor incontinence while no details on specific symptoms are specified in the GOG 99 trial report. A higher risk of late urinary side-effects is reported for cervical cancer, which may be related to the higher doses of radiation therapy used ([@bib17]). In an observational study by [@bib30], no increased occurrence of bladder dysfunction was reported at 24 months\' follow-up in 94 early-stage cervical cancer patients treated with postoperative EBRT, compared with surgery alone or control women. Nearly, every study shows that late post-radiation urinary morbidity continues to progress decades after radiation therapy. The short follow-up period and the restriction to only two questions concerning micturition may have contributed to the results reported by [@bib30]. In a population-based survey of 291 cervical cancer survivors with an average follow-up period of 6.6 years, self-reported symptoms of frequent micturition were reported by 42 and 45% following radiation therapy alone or postoperative EBRT ([@bib24]). Urinary leakage was reported by 19 and 26% and difficulties emptying the bladder in 6% and 11%, respectively. These results are in line with our findings. Besides difficulties emptying the bladder, urinary incontinence, urgency and cystitis, the survivors in our study also reported difficulties feeling a full bladder. Our results indicate that late side-effects from the urinary tract following radiation therapy are underestimated and underreported.

Most previous population-based surveys addressing the impact of radiation therapy on normal tissues have focused on sexuality in survivors after treatment of cervical cancer. In a population-based cohort study of long-term early stage cervical cancer, survivors reported more sexual dysfunction resulting in considerable distress, compared with control women ([@bib8]). The impact of radiation therapy on sexual function has since then been confirmed in several publications ([@bib22]; [@bib18]; [@bib29]; [@bib24]). Some results support the positive effect of using vaginal dilators to prevent development of vaginal stenosis following radiation therapy as reviewed by the Cochrane Collaboration ([@bib13]).

We have in a previous publication reported on the findings of higher occurrence of pubic bone symptoms and increased frequency of pubic bone pain with mean absorbed dose exceeding 52.5 Gy to the pubic bone ([@bib39]). Cancer survivors in our study treated with radiation therapy alone also reported a higher prevalence of hip pain. The potential relationship between hip pain and radiation dose will be addressed in a coming report from our group.

Lymph oedema is a common late symptom among gynaecological cancer survivors ([@bib9]). In a population-based mailed survey of 802 gynaecological cancer survivors ([@bib5]), 25% were diagnosed with lymph oedema or had symptomatic lower limb swelling. A higher prevalence was observed in vulvar cancer survivors. These results are consistent with our findings. The survivors in our study also report a higher occurrence of heaviness or swollen lower abdomen. The prevalence was higher after radiation therapy alone than after combination of surgery and radiation therapy. One may speculate that fibrosis or occlusion of lymph vessels after radiation therapy may be involved in the mechanism behind this symptom.

Some of the strengths of this study are the large population-based patient cohort and the high participation rate. Access to all medical records has ensured correct information regarding clinical characteristics and detailed knowledge of administered treatment. The construction of the study-specific questionnaire in close cooperation with the gynaecological cancer survivors, comprehensive face-to-face validation and the use of a privately answered questionnaire lowered the risk for measurement errors and eliminated interviewer-induced bias. By asking for symptom occurrence during the past 6 months, we avoided capturing temporary symptoms produced by chance and at the same time minimised risk of recall-induced problems. Symptoms were atomised, subdivided into very specific questions, which may have contributed to survivors\' multitude of symptoms. In an effort to increase participation, we did not include subjects over the age of 80 years. We cannot, however, exclude the possibility that non-participating subjects would have answered differently. The loss of information from part of the targeted-person-time may result in a deviation between the true effect measure and the observed effect measure in a way that is unpredictable. The minimum internal response rate for individual questions was 81% (502 out of 616) for survivors and 88% (302 out of 344) for control women in questions dealing with sexuality. This may negatively affect the generalisability of the study result. Individuals who failed to respond to a certain question were excluded from the analysis of that outcome. In all tables, the response rates can be assessed through the denominator that is presented for all items.

Research regarding long-term treatment effects in cancer survivors will give us knowledge for developing new strategies in cancer treatment. Updated recommendations are gradually introduced into clinical use. Several randomised clinical trials investigating the outcome of adjuvant radiation therapy in endometrial cancer patients have shown an increased risk of late radiation therapy-induced morbidity but without survival benefit ([@bib11]; [@bib23]; [@bib28]). Hence, adjuvant radiation therapy is nowadays seldom given to endometrial patients with low-intermediate risk malignancy. A potential new treatment approach is TGF-*β*, which is a promising target for preventing radiotherapy-induced fibrosis ([@bib4]). In addition, we also believe that prevention of some symptoms may be achieved by optimising radiation delivery by improved target imaging and treatment planning with dose-constraints guidelines and by the use of intensity modulated radiation therapy ([@bib34]).

In this first stage of our gynaecological cancer survivorship programme, we report on the occurrence of symptoms from normal tissues after pelvic irradiation. In the second stage of our programme, we will continue the reporting of the impact of specific symptoms on daily life activities and quality of life. The study cohort is highly heterogeneous and these circumstances contribute to variability of the absorbed dose of ionising radiation to the normal tissue surrounding the target, which will enable us to study the dose-volume effects of radiation therapy to normal-tissues in relation to self-reported symptoms. In the third stage of our survivorship programme, we intend to explore which levels of ionising radiation delivered to specific volumes of normal tissue surrounding the target that contribute to the occurrence of a specific symptom, which can affect quality of life. This may help the radiotherapist to optimise dose planning and thereby hopefully reduce the symptom burden among future long-term gynaecological cancer survivors.
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###### Demographic characteristics for gynaecological cancer survivors and control women

                                                       **Cancer survivors, *N*=616 (%)**   **Control women, *N*=344 (%)**   ***P*-value**[a](#t1-fn3){ref-type="fn"}
  ---------------------------------------------------- ----------------------------------- -------------------------------- ------------------------------------------
  *Age*                                                                                                                     \<0.001
   28--49                                              64/616 (10)                         102/342 (30)                      
   50--59                                              102/616 (17)                        80/342 (23)                       
   60--69                                              233/616 (38)                        78/342 (23)                       
   70--79                                              217/616 (35)                        82/342 (24)                       
   Median age, years (range)                           66.0 (28--79)                       57.5 (36--79)                     
                                                                                                                             
  *Marital status*                                     0.009                                                                
   Married or living with a partner                    344/613 (56)                        220/344 (64)                      
   Has a partner but lives alone                       37/613 (6)                          22/344 (6)                        
   Widow                                               84/613 (14)                         37/344 (11)                       
   Single                                              148/613 (24)                        65/344 (19)                       
                                                                                                                             
  *Education*                                          \<0.001                                                              
   Elementary school                                   196/615 (32)                        69/342 (20)                       
   Secondary school                                    236/615 (38)                        146/342 (43)                      
   College or university                               183/615 (30)                        127/342 (37)                      
                                                                                                                             
  *Employment*                                         \<0.001                                                              
   Student                                             5/613 (\<1)                         2/343 (\<1)                       
   Unemployed                                          12/613 (2)                          6/343 (2)                         
   Employed                                            202/613 (33)                        188/343 (55)                      
   Housewife, other                                    11/613 (2)                          5/343 (1)                         
   On sick leave                                       11/613 (2)                          10/343 (3)                        
   Disability pension                                  53/613 (9)                          15/343 (4)                        
   Retired                                             319/613 (52)                        117/343 (34)                      
                                                                                                                             
  *Country of birth*                                   \<0.001                                                              
   Sweden                                              510/614 (83)                        316/344 (92)                      
                                                                                                                             
  *Place of residency*                                 0.402                                                                
   Rural district                                      52/615 (10)                         34/341 (10)                       
   Village/town                                        191/615 (31)                        93/341 (27)                       
   \>500 000 citizen                                   372/615 (60)                        214/341 (63)                      
                                                                                                                             
  *Smoking*                                                                                                                 0.608
   Current smoker                                      144/607 (24)                        88/343 (26)                       
   Former smoker                                       183/607 (30)                        108/343 (31)                      
   Never smoker                                        280/607 (46)                        147/343 (43)                      
                                                                                                                             
  *BMI*[b](#t1-fn4){ref-type="fn"}                     0.256                                                                
   \<18.5 (underweight)                                16/575 (3)                          5/327 (2)                         
   18.5--25.0 (normal weight)                          261/575 (45)                        163/327 (50)                      
   25.0--30.0 (overweight)                             201/575 (35)                        116/327 (35)                      
   \>30.0 (obese)                                      97/575 (17)                         43/327 (13)                       
   BMI, median (range)                                 25.1 (16.0--53.1)                   24.7 (13.4--44.5)                 
                                                                                                                             
  *Exercise*                                           0.001                                                                
   Never                                               76/599 (13)                         20/341 (6)                        
   Occasionally -- at least once a month               78/599 (13)                         59/341 (17)                       
   At least once a week                                445/599 (74)                        262/341 (77)                      
                                                                                                                             
  *Parity*                                                                                                                  \<0.001
   Nulli (never given birth)                           154/615 (25)                        45/344 (13)                       
   1--3 para                                           410/615 (67)                        280/344 (81)                      
   \>3 para                                            51/615 (8)                          19/344 (6)                        
                                                                                                                             
  *Delivery*                                                                                                                 
   Fast \<5 h                                          250/607 (41)                        147/342 (43)                     0.631
   Slow \>24 h                                         141/607 (23)                        88/342 (26)                      0.386
   Vacuum                                              41/607 (7)                          43/342 (13)                      0.004
   Forceps                                             12/607 (2)                          7/342 (2)                        1.000
   Episiotomy                                          132/607 (22)                        117/342 (34)                     \<0.001
   Caesarean                                           28/607 (5)                          40/342 (12)                      0.001
   Breech birth                                        18/607 (3)                          20/342 (6)                       0.038
                                                                                                                             
  *Delivery with birth weight \>4 kg*                                                                                       0.266
   1                                                   78/612 (13)                         54/344 (16)                       
   ⩾2                                                  42/612 (7)                          29/344 (8)                        
                                                                                                                             
  *Pelvic floor injury*                                                                                                     
   Vaginal or perineal injury                          111/599 (19)                        101/342 (30)                     \<0.001
   Anal sphincter injury                               18/593 (3)                          18/342 (5)                       0.111
                                                                                                                             
  *Intercurrent diseases*                                                                                                   
   Previous abdominal surgery                          264/616 (43)                        156/344 (45)                     0.456
   Diabetes mellitus                                   58/611 (9)                          17/338 (5)                       0.016
   Angina pectoris                                     32/600 (5)                          11/341 (3)                       0.147
   Cardiac infarction                                  18/600 (3)                          5/341 (1)                        0.188
   Heart failure                                       33/600 (6)                          8/341 (2)                        0.029
   Hypertension                                        227/600 (38)                        91/341 (27)                      \<0.001
   Crohn\'s disease, treatment for                     1/594 (\<1)                         0/332 (0)                        1.000
   Ulcerative colitis, treatment for                   5/581 (\<1)                         7/327 (2)                        0.131
   Irritable bowel syndrome, treatment for             27/594 (4)                          13/332 (4)                       0.737
   Haemorrhoids, treatment for                         61/591 (10)                         45/322 (14)                      0.105
   Lactose intolerance                                 33/598 (6)                          13/331 (4)                       0.334
   Gluten intolerance                                  8/604 (1)                           3/330 (\<1)                      0.755
   Pelvic organ prolapse, treatment for                12/596 (2)                          13/332 (4)                       0.094
   Rheumatism                                          37/600 (6)                          19/341 (6)                       0.775
   Kidney disease                                      19/600 (3)                          8/341 (2)                        0.546
   Lung disease                                        40/600 (7)                          12/341 (4)                       0.053
   Thrombosis                                          47/600 (8)                          16/341 (5)                       0.077
   Osteoporosis                                        58/600 (10)                         25/341 (7)                       0.235
   Psychological disorders                             78/600 (13)                         43/341 (13)                      0.919
   Neurological disorders[c](#t1-fn5){ref-type="fn"}   15/600 (3)                          3/341 (\<1)                      0.089
                                                                                                                             
  *Medication*                                                                                                              
   Using any kind of medication                        439/606 (72)                        194/338 (57)                     \<0.001
   Oestrogen                                           224/606 (37)                        50/339 (15)                      \<0.001

Abbreviation: BMI=body mass index.

Denominator is dependent on number of respondents answering a specific item and may differ from the maximum sum. Percentage may not total hundred because of rounding.

*P*-value according to Fisher\'s exact test.

Current BMI at the time the questionnaire was completed.

Parkinson\'s disease, multiple sclerosis and epilepsy.

###### Late symptoms during the past 6 months among gynaecological cancer survivors treated with pelvic radiation therapy with or without surgery and control women

                                                                                                  **Survivors, *N=*616 (%)**   **Controls, *N=*344 (%)**  **Survivors *vs* controls Age-adjusted RR (95% CI )**    **RT with surgery, *N=*549 (%)**  **RT with surgery *vs* controls Age-adjusted RR (95% CI)**    **RT without surgery, *N*=67 (%)**  **RT without surgery *vs* controls Age-adjusted RR (95% CI)**
  ---------------------------------------------------------------------------------------------- ---------------------------- --------------------------- ------------------------------------------------------- ---------------------------------- ------------------------------------------------------------ ------------------------------------ ---------------------------------------------------------------
  *Anal-sphincter symptoms*                                                                                                                                                                                                                                                                                                                            
   Emptying of all stools into clothing without forewarning at least occasionally                        70/606 (12)                  3/344 (0.9)         **12.7 (4.0--40.3)**                                               55/546 (10)             **8.8 (2.8--28.3)**                                                       15/60 (25)              **30.3 (9.1--101.1)**
   Leakage of loose stools while awake at least occasionally                                             199/608 (33)                 18/344 (5)          **6.0 (3.7--9.6)**                                                 171/545 (31)            **5.5 (3.4--8.8)**                                                        28/63 (44)              **8.5 (5.0--14.5)**
   Leakage of loose stools while asleep at least occasionally                                            72/611 (12)                   8/343 (2)          **5.5 (2.6--11.4)**                                                58/548 (11)             **4.4 (2.1--9.2)**                                                        14/63 (22)              **9.8 (4.3--22.4)**
   Anal leakage of mucus while asleep at least occasionally                                               32/607 (5)                   4/344 (1)          **4.9 (1.7--14.1)**                                                 25/545 (5)             **3.3 (1.1--9.4)**                                                        7/62 (11)               **9.7 (2.9--32.3)**
   Leakage of solid stools while awake at least occasionally                                              46/607 (8)                   5/344 (1)          **4.4 (1.7--11.0)**                                                 37/544 (7)             **3.4 (1.4--8.7)**                                                        9/63 (14)               **9.3 (3.2--27.0)**
   Faecal leakage without forewarning despite previous defaecation at least occasionally                 188/605 (31)                 23/344 (7)          **4.2 (2.8--6.4)**                                                 168/545 (31)            **3.9 (2.6--6.0)**                                                        20/60 (33)              **4.8 (2.8--8.2)**
   Defaecation urgency with faecal leakage at least occasionally                                         298/603 (49)                 42/343 (12)         **4.0 (3.0--5.4)**                                                 262/541 (48)            **3.8 (2.8--5.2)**                                                        36/62 (58)              **4.8 (3.3--6.8)**
   Foul smelling flatulence at least once a week                                                         116/602 (19)                 22/343 (6)          **3.7 (2.4--5.8)**                                                 102/541 (19)            **3.8 (2.4--5.9)**                                                        14/61 (23)              **3.6 (2.0--6.7)**
   Anal leakage of mucus while awake at least occasionally                                               87/603 (14)                  14/343 (4)          **3.5 (2.0--6.1)**                                                 76/542 (14)             **3.2 (1.8--5.6)**                                                        11/61 (18)              **4.1 (1.9--8.6)**
   Self-perception of faecal odour at least occasionally                                                 108/606 (18)                 18/340 (5)          **3.3 (2.0--5.4)**                                                 95/544 (17)             **3.1 (1.9--5.2)**                                                        13/62 (21)              **4.0 (2.1--7.8)**
   Involuntary flatulence at least once a week                                                           127/606 (21)                 33/343 (10)         **2.4 (1.7--3.5)**                                                 111/545 (20)            **2.3 (1.5--3.3)**                                                        16/61 (26)              **2.8 (1.7--4.8)**
   Unwanted defaecation while emptying bladder at least occasionally                                     238/603 (39)                 57/342 (17)         **2.4 (1.9--3.2)**                                                 213/541 (39)            **2.4 (1.8--3.1)**                                                        25/62 (40)              **2.3 (1.6--3.4)**
   Anal leakage of blood while awake at least occasionally                                                42/608 (7)                  12/343 (4)          **2.0 (1.1--3.9)**                                                  37/545 (7)             2.0 (1.0--3.9)                                                             5/63 (8)               2.2 (0.8--6.7)
   Involuntary loud flatulence at least occasionally                                                     359/607 (59)                150/344 (44)         **1.4 (1.2--1.6)**                                                 314/546 (58)            **1.3 (1.1--1.5)**                                                        45/61 (74)              **1.7 (1.4--2.1)**
                                                                                                                                                                                                                                                                                                                                                        
  *Bowel symptoms*                                                                                                                                                                                                                                                                                                                                     
   Defaecation urgency at least once a week                                                              175/602 (29)                 19/341 (6)          **5.7 (3.5--9.1)**                                                 157/542 (29)            **5.7 (3.5--9.1)**                                                        18/60 (30)              **6.0 (3.3--10.8)**
   Protracted abdominal pain lasting \>1 year, yes                                                       69/593 (12)                  15/339 (4)          **3.2 (1.9--5.6)**                                                 59/532 (11)             **3.1 (1.7--5.5)**                                                        10/61 (16)              **3.8 (1.8--7.9)**
   Loose stools at least once a week                                                                     234/602 (39)                 48/344 (14)         **3.0 (2.2--3.9)**                                                 205/540 (38)            **2.9 (2.1--3.9)**                                                        29/62 (47)              **3.5 (2.4--5.1)**
   Abdominal pain and vomiting at least occasionally                                                     60/605 (10)                  13/344 (4)          **2.6 (1.4--4.7)**                                                  49/545 (9)             **2.2 (1.2--4.1)**                                                        11/60 (18)              **4.8 (2.2--10.1)**
   Mucus in stools at least occasionally                                                                 156/607 (26)                 45/343 (13)         **2.1 (1.5--3.0)**                                                 143/545 (26)            **2.2 (1.6--3.0)**                                                        13/62 (21)              1.6 (0.9--2.8)
   Abdominal bloating at least once a week                                                               147/605 (24)                 60/342 (18)         **1.8 (1.4--2.3)**                                                 129/544 (24)            **1.8 (1.3--2.3)**                                                        18/61 (30)              **1.8 (1.1--2.7)**
   Rectal bleeding at least occasionally                                                                 103/604 (17)                 42/341(12)          **1.6 (1.1--2.2)**                                                 92/545 (17)             **1.6 (1.2--2.4)**                                                        11/59 (19)              1.5 (0.8--2.8)
   Abdominal pain and stools at least occasionally                                                       198/602 (33)                 79/343 (23)         **1.6 (1.3--2.0)**                                                 171/541 (32)            **1.5 (1.2--1.9)**                                                        27/61 (44)              **2.0 (1.4--2.8)**
   Abdominal pain at least occasionally                                                                  307/604 (51)                137/340 (40)         **1.4 (1.2--1.6)**                                                 272/544 (50)            **1.4 (1.2--1.6)**                                                        35/60 (58)              **1.5 (1.2--1.9)**
   Abdominal pain and bloating at least occasionally                                                     228/603 (38)                106/340 (31)         **1.4 (1.2--1.7)**                                                 199/542 (37)            **1.4 (1.2--1.7)**                                                        29/61 (48)              **1.6 (1.2--2.1)**
                                                                                                                                                                                                                                                                                                                                                        
  *Urinary tract symptoms*                                                                                                                                                                                                                                                                                                                             
   Difficulty feeling the need to empty bladder at least occasionally                                     56/604 (9)                  11/343 (3)          **2.8 (1.5--5.4)**                                                  46/544 (8)             **2.5 (1.3--5.0)**                                                        10/60 (17)              **5.1 (2.3--11.3)**
   Difficulty emptying bladder at least occasionally                                                      49/602 (8)                  11/343 (3)          **2.7 (1.4--5.2)**                                                  43/542 (8)             **2.7 (1.4--5.5)**                                                        6/60 (10)               **3.2 (1.3--8.4)**
   Difficulty feeling full bladder at least occasionally                                                 90/602 (15)                  18/342 (5)          **2.7 (1.6--4.5)**                                                 76/543 (14)             **2.4 (1.4--4.1)**                                                        14/59 (24)              **4.5 (2.4--8.4)**
   Haematuria at least occasionally                                                                       20/606 (3)                   5/344 (1)          2.5 (0.9--6.9)                                                      16/546 (3)             2.4 (0.8--6.8)                                                             4/60 (7)               **5.0 (1.4--17.8)**
   Straining to initiate emptying of bladder at least occasionally                                       77/605 (13)                  21/343 (6)          **2.2 (1.4--3.7)**                                                 68/545 (12)             **2.4 (1.5--3.9)**                                                        9/60 (15)               **2.5 (1.2--5.3)**
   Painful emptying of bladder at least occasionally                                                     60/605 (10)                  20/341 (6)          **2.0 (1.2--3.3)**                                                 52/545 (10)             **1.9 (1.1--3.3)**                                                        8/60 (13)               **2.3 (1.1--5.0)**
   Urinary incontinence without urinary urgency at least occasionally                                    88/603 (15)                  24/342 (7)          **1.8 (1.2--2.9)**                                                 81/543 (15)             **1.9 (1.2--3.0)**                                                        7/60 (12)               1.6 (0.7--3.6)
   Night-time emptying of bladder at least twice per night or more, yes                                  222/607 (37)                 58/341 (17)         **1.8 (1.4--2.4)**                                                 199/548 (36)            **1.8 (1.4--2.4)**                                                        23/59 (39)              **2.2 (1.5--3.2)**
   Need of antibiotics because of urinary tract infection twice or more, yes                             93/605 (15)                  31/344 (9)          **1.6 (1.1--2.3)**                                                 86/545 (16)             **1.7 (1.1--2.5)**                                                        7/60 (12)               1.3 (0.6--2.9)
   Urinary incontinence because of urinary urgency at least occasionally                                 209/607 (34)                 66/342 (19)         **1.6 (1.2--2.0)**                                                 186/545 (34)            **1.5 (1.2--2.0)**                                                        23/62 (37)              **1.8 (1.2--2.7)**
   Slow emptying of bladder at least occasionally                                                        122/605 (20)                 47/344 (14)         **1.6 (1.2--2.2)**                                                 106/546 (19)            **1.5 (1.1--2.2)**                                                        16/59 (27)              **2.0 (1.2--3.3)**
   Self-perception of urine odour at least occasionally                                                  149/605 (25)                 62/341(18)          **1.4 (1.1--1.9)**                                                 126/544 (23)            **1.3 (1.0--1.8)**                                                        23/61 (38)              **2.1 (1.4--3.0)**
   Urinary urgency at least occasionally                                                                 346/605 (57)                139/343 (41)         **1.3 (1.1--1.5)**                                                 308/544 (57)            **1.3 (1.1--1.5)**                                                        38/61 (62)              **1.5 (1.2--1.8)**
   Feeling of incomplete bladder emptying at least occasionally                                          232/604 (38)                101/343 (29)         **1.3 (1.1--1.6)**                                                 203/544 (37)            **1.3 (1.0--1.6)**                                                        29/60 (48)              **1.6 (1.2--2.2)**
                                                                                                                                                                                                                                                                                                                                                        
  *Symptoms related to sexuality*                                                                                                                                                                                                                                                                                                                      
   Protracted genital pain lasting for \>1 year, yes                                                      28/593 (5)                   4/339 (1)          **5.0 (1.7--14.5)**                                                 21/532 (4)             **4.3 (1.4--13.0)**                                                       7/61 (11)               **9.6 (2.9--31.8)**
   Genital bleeding during or after intercourse at least once, yes                                        54/585 (9)                  13/329 (4)          **3.7 (2.1--6.7)**                                                  45/523 (9)             **3.6 (2.0--6.7)**                                                        9/62 (15)               **3.9 (1.8--8.4)**
   Deep dyspareunia when having intercourse, at least a little                                           101/583 (17)                 23/330 (7)          **3.7 (2.4--5.7)**                                                 90/521 (17)             **3.7 (2.4--5.8)**                                                        11/62 (18)              **3.0 (1.6--5.7)**
   Vaginal lubrication when sexually aroused, no                                                          39/577 (7)                   7/333 (2)          **2.9 (1.3--6.4)**                                                  37/517 (7)             **2.9 (1.3--6.5)**                                                         2/60 (3)               1.6 (0.3--7.5)
   Decreased ability for intercourse leading to lower intercourse frequency, at least a little           176/575 (31)                 37/327 (11)         **2.9 (2.1--4.1)**                                                 160/515 (31)            **2.9 (2.0--4.0)**                                                        11/60 (18)              **2.5 (1.5--4.1)**
   Vaginal elasticity, no                                                                                172/502 (34)                 41/302 (14)         **1.8 (1.3--2.4)**                                                 148/451 (33)            **1.6 (1.2--2.2)**                                                        24/51 (47)              **2.5 (1.7--3.7)**
   Genital swelling when sexually aroused, no                                                            82/571 (14)                  35/327 (11)         **1.5 (1.0--2.2)**                                                 72/512 (14)             1.5 (1.0--2.2)                                                            10/59 (17)              1.6 (0.9--3.1)
   Superficial dyspareunia when having intercourse, at least a little                                    140/584 (24)                 67/330 (20)         **1.5 (1.2--2.0)**                                                 125/523 (24)            **1.5 (1.1--2.0)**                                                        15/61 (25)              1.4 (0.8--2.2)
   Sensitivity to touch inside vagina, no                                                                221/540 (41)                 65/310 (21)         **1.3 (1.0--1.6)**                                                 192/485 (40)            1.2 (1.0--1.5)                                                            29/55 (53)              **1.7 (1.3--2.2)**
   Sensitivity to touch of labia and clitoris, no                                                        186/558 (33)                 61/320 (19)         1.2 (0.9--1.5)                                                     163/501 (33)            1.1 (0.9--1.4)                                                            23/57 (40)              **1.5 (1.1--2.1)**
                                                                                                                                                                                                                                                                                                                                                        
  *Pelvic bone symptoms*                                                                                                                                                                                                                                                                                                                               
   Pubic pain when walking indoors at least occasionally                                                  46/603 (8)                   6/343 (2)          **4.9 (2.1--11.6)**                                                 35/542 (6)             **4.1 (1.7--10.2)**                                                       11/61 (18)              **10.3 (4.0--26.7)**
   Pubic pain when walking outdoors 500 m at least occasionally                                           42/596 (7)                   7/343 (2)          **3.7 (1.7--8.4)**                                                  34/536 (6)             **3.3 (1.4--7.7)**                                                        8/60 (13)               **6.6 (2.5--17.5)**
   Pubic pain, yes                                                                                       67/603 (11)                  12/339 (4)          **3.4 (1.9--6.4)**                                                 53/544 (10)             **3.0 (1.6--5.7)**                                                        14/59 (24)              **7.0 (3.5--14.2)**
   Hip pain, yes                                                                                         212/599 (35)                113/343 (33)         1.0 (0.8--1.2)                                                     182/538 (34)            0.9 (0.8--1.2)                                                            30/61 (49)              **1.5 (1.1--2.0)**
   Hip pain when walking outdoors 500 m at least occasionally                                            193/598 (32)                102/340 (30)         1.0 (0.8--1.3)                                                     165/536 (31)            1.0 (0.8--1.2)                                                            28/62 (45)              **1.5 (1.1--2.0)**
   Sacral pain, yes                                                                                      232/600 (39)                179/344 (52)         **0.8 (0.7--0.9)**                                                 196/539 (36)            **0.7 (0.6--0.8)**                                                        36/61 (59)              1.1 (0.9--1.4)
                                                                                                                                                                                                                                                                                                                                                        
  *Lower abdomen and leg symptoms*                                                                                                                                                                                                                                                                                                                     
   Erysipelas on abdomen or legs, yes                                                                     17/597 (3)                   3/336 (1)          **3.6 (1.0--12.8)**                                                 14/537 (3)             **4.0 (1.1--14.5)**                                                        3/60 (5)               **5.2 (1.1--25.1)**
   Lower abdominal heaviness at least occasionally                                                       119/600 (20)                 38/344 (11)         **2.1 (1.5--3.0)**                                                 101/540 (19)            **2.1 (1.4--3.0)**                                                        18/60 (30)              **2.7 (1.7--4.5)**
   Pain in lower abdomen in connection with oedema at least occasionally                                 92/607 (15)                  33/343 (10)         **1.9 (1.3--2.8)**                                                 75/546 (14)             **1.7 (1.1--2.6)**                                                        17/61 (28)              **3.0 (1.8--5.0)**
   Leg pain in connection with oedema at least occasionally                                              164/606 (27)                 54/342 (16)         **1.7 (1.3--2.3)**                                                 145/545 (27)            **1.7 (1.2 (2.2)**                                                        19/61 (31)              **2.0 (1.3--3.2)**
   Swollen lower abdomen at least occasionally                                                           121/599 (20)                 51/342 (15)         **1.7 (1.3--2.4)**                                                 106/538 (20)            **1.8 (1.3--2.5)**                                                        15/61 (25)              **1.7 (1.0--2.8)**
   Protracted leg pain lasting \>1 year, yes                                                             134/593 (23)                 48/339 (14)         **1.5 (1.1--2.1)**                                                 115/532 (22)            **1.4 (1.0--2.0)**                                                        19/61 (31)              **2.2 (1.4--3.4)**
   Swollen legs at least occasionally                                                                    218/606 (36)                 94/344 (27)         **1.4 (1.1--1.7)**                                                 197/546 (36)            **1.4 (1.1--1.9)**                                                        21/60 (35)              1.4 (0.9--2.0)
   Heavy legs at least occasionally                                                                      210/606 (35)                 97/344 (28)         **1.1 (1.1--1.6)**                                                 186/546 (34)            **1.3 (1.0--1.6)**                                                        24/60 (40)              **1.4 (1.0--2.1)**

Abbreviations: CI=confidence interval; RR=relative risk; RT=radiation therapy.

Bold entries indicate statistic significance. The symptoms are sorted into anatomical region of supposed origin and in size order for RR, the number in the denominator may vary because of missing information.
